Scientists reverse Huntington’s disease in animal model using precision medicine.


By adjusting the levels of a key signaling protein, researchers from The Children’s Hospital of Philadelphia (CHOP) improved motor function and brain abnormalities in experimental animals with a form of Huntington’s disease, a severe neurodegenerative disorder. The new findings are expected to lay the groundwork of a novel treatment for people with this fatal, progressive disease.  The opensource study is published in the journal Neuron.

The current study shows the intricate workings of a biological pathway crucial to the development of Huntington’s disease, and is highly relevant to drug development.  The team state that the results in animals open the door to a promising potential therapy, based on carefully manipulating the dysregulated pathway to treat this devastating human disease.  The team add that restoring proper balance to these delicate biological processes may offer even broader benefits in treating other neurological diseases, such as amyotrophic lateral sclerosis (ALS), fragile X mental retardation and autism.

Huntington’s disease is an incurable, inherited disease entailing progressive loss of brain cells and motor function, usually beginning in midlife. A defective gene produces repeated copies of a protein called huntingtin, or HTT. The mutant HTT protein (mHTT) particularly damages a brain region called the striatum, where it interferes with normal cell growth and other fundamental biological events. The resulting disease includes involuntary movements and severe cognitive and emotional disturbances. About 30,000 Americans have Huntington’s disease (HD).

Neuroscientists already knew that a signaling protein called mTORC1 that regulates cell growth and metabolism plays a major role in HD. Many researchers have proposed that inhibiting or shutting off the mTORC1 pathway, which interacts with the deleterious mHTT proteins, could help treat HD.

The current study contradicts those assumptions. The researchers showed that the mTORC1 pathway is already impaired in Huntington’s disease, and that improving how the pathway functions actually has a protective effect.  However, restoring that pathway must be done very carefully to avoid further harm meaning that either too much or too little is detrimental.

In mice bred to model features of Huntington’s disease, the team injected bioengineered viruses as a gene therapy tool to carry DNA that directed the production of regulatory proteins called Rheb and Rhes. Both proteins act along the mTORC1 pathway. The treated mice had improvements in brain volume and in their movements. The mice had improved metabolic functions as well, such as cholesterol levels, dopamine signaling and mitochondrial activity (an indicator of cellular energy production). There also were increases in autophagy, an organism’s cleanup process that clears out and recycles mHTT and other proteins.

The team also note that in the HD mice, brain areas that had begun to atrophy recovered volume and permitted better motor function after the researchers restored mTORC1 activity to more normal levels.  This showed that brain cells are capable of responding even after disease onset, and hints at the potential for reversing Huntington’s disease.

The team state that much work remains to translate these scientific findings into a clinical treatment adding that the medical community must identify drug candidates that appropriately activate the mTORC1 pathway. Although gene therapy vectors delivered to brain were used for this research, the researchers envision developing a small molecule that can appropriately modulate this pathway. Such a treatment might be combined with a gene therapy approach, also being pursued by the medical community, and delivered directly to the brain to curtail mHTT expression.

More broadly the team state that restoring mTORC1 activity to normal levels may benefit patients with other neurological diseases. Fragile X mental retardation and autism both feature overactive mTORC1 activity, while mTORC1 is reduced in ALS and HD.  The team summise that the work highlights that it’s essential to control its activity to find the appropriate balance for each disease.

Source:  Newswise

 

mTORC1 Regulates Genes Involved in mHTT Aggregate Clearance.  AAV.eGFP transduction of hippocampus.  eGFP expression in the hippocampus of N171-82Q mice 2 weeks after AAV1.  eGFP injection into the dentategyrus at 10 weeks of age.  Reinstating Aberrant mTORC1 Activity in Huntington’s Disease Mice Improves Disease Phenotypes.  Lee et al 2015.

mTORC1 Regulates Genes Involved in mHTT Aggregate Clearance. AAV.eGFP transduction of hippocampus. eGFP expression in the hippocampus of N171-82Q mice 2 weeks after AAV1. eGFP injection into the dentategyrus at 10 weeks of age. Reinstating Aberrant mTORC1 Activity in Huntington’s Disease Mice Improves Disease Phenotypes. Lee et al 2015.

 

One comment

  • ibrahim MohamedSaeed shnawa

    It is rather interesting findings especially those using combined gene and the other theraputic modalities for treating HD.

    Like

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s